Bofanglutide: A Biweekly GLP-1 RA Showing Promise

Ever dreamt of a powerful new tool in metabolic health, one that might only need attention once every two weeks? Imagine a peptide that not only helps shed pounds but also brings blood sugar levels into line. This isn't science fiction; it's the exciting world of Bofanglutide, a novel glucagon-like peptide-1 receptor agonist (GLP-1 RA) that's currently making waves in clinical trials.

What is Bofanglutide?

Bofanglutide is a synthetic peptide, specifically a glucagon-like peptide-1 receptor agonist (GLP-1 RA) (PMID 41760612). These types of peptides mimic the natural hormone GLP-1, which plays a crucial role in regulating appetite and blood glucose. What makes Bofanglutide particularly intriguing is its proposed dosing schedule: it's being developed as a biweekly (once every two weeks; Q2W) or once-weekly (QW) treatment (PMID 41760612, PMID 42372276, PMID 41956096). There's also an oral formulation co-formulated with SNAC under investigation (PMID 42442555). The molecule has also been referred to as GZR18 in some studies (PMID 41956096, PMID 42320483).

Why researchers are excited

Researchers are buzzing about Bofanglutide primarily due to its striking efficacy in reducing body weight and improving glycemic control, observed in several recent phase 2b clinical trials. Imagine a reduction in body weight ranging from nearly 10% to over 16% in just 30 weeks for individuals with overweight or obesity (PMID 41760612)! This kind of impact is turning heads in the metabolic research community.

Furthermore, in trials involving individuals with type 2 diabetes, Bofanglutide has demonstrated significant reductions in glycated hemoglobin (HbA1c) levels, a key marker for long-term blood sugar control. In fact, some bofanglutide regimens showed even greater HbA1c reductions compared to a commonly used GLP-1 RA, semaglutide, in a head-to-head trial (PMID 42372276).

The potential for less frequent dosing (biweekly or even once daily orally) also represents a significant advancement, potentially improving convenience and adherence for patients compared to more frequent options (PMID 41760612, PMID 42442555).

What the studies found

Bofanglutide has been evaluated in multiple clinical trials, primarily in Chinese adults, showing notable results across different endpoints. Here's a snapshot of key findings:

| Study | Model | Key finding | PMID | |---|---|---|---| | Phase 2b trial (NCT06256562) | Adults with overweight/obesity | Mean percentage change in body weight from baseline to week 30 ranged from -9.75% to -16.69% with bofanglutide, vs. -1.15% with placebo. | PMID 41760612 | | Phase 2b trial (NCT06256549) | Adults with T2DM | HbA1c level change from baseline to week 24 ranged from -1.87% to -2.32% for bofanglutide, vs. -1.60% for semaglutide. | PMID 42372276 | | Phase 1b/2a trial (NCT06256536) | Chinese adults with overweight/obesity | Least-squares mean change in body weight was -9.36% (Part A) and up to -17.8% (QW, Part B) for GZR18 (bofanglutide) vs. 6.68% and 0.7% for placebo. | PMID 41956096 | | Phase 1b/2a trial (NCT06256523) | Chinese adults with T2DM | GZR18 (bofanglutide) significantly reduced HbA1c: -1.32% (Part A) and -1.81% (Part B) vs. 0.86% and 0.12% for placebo. | PMID 42320483 | | Oral formulation trial | Healthy Chinese participants | Oral bofanglutide was safe and well tolerated; a 60-minute post-dose fast approximately doubled exposure compared to a 30-minute fast. | PMID 42442555 |

In the phase 2b trial for overweight and obesity, participants receiving Bofanglutide experienced a mean body weight reduction ranging from -9.75% to -16.69% by week 30, a stark contrast to the -1.15% seen in the placebo group (PMID 41760612). These reductions were statistically significant, painting a vivid picture of its efficacy.

For individuals with type 2 diabetes, Bofanglutide demonstrated impressive glycemic control. In one trial, HbA1c levels decreased by -1.87% to -2.32% from baseline over 24 weeks with various bofanglutide regimens, compared to a -1.60% reduction with semaglutide (PMID 42372276). Some doses of bofanglutide showed even greater HbA1c reductions than semaglutide (PMID 42372276). Other trials (using the name GZR18) also noted significant HbA1c reductions, for example, -1.81% versus 0.12% for placebo in one part of a study (PMID 42320483).

The safety profile across these trials indicates that Bofanglutide is generally well-tolerated. The most common adverse events were gastrointestinal, mostly mild-to-moderate in severity, and consistent with effects seen with other GLP-1 RAs (PMID 41760612, PMID 42442555, PMID 42372276, PMID 41956096, PMID 42320483). Notably, severe hypoglycemia was rare or absent in these studies (PMID 42442555, PMID 42372276, PMID 42320483).

An oral formulation of Bofanglutide is also under investigation. In healthy Chinese participants, it was found to be safe and well tolerated, with its exposure being significantly influenced by post-dose fasting duration (PMID 42442555).

How it's thought to work

As a GLP-1 receptor agonist, Bofanglutide mimics the action of natural glucagon-like peptide-1 (PMID 41760612). GLP-1 is a hormone that plays several key roles in metabolic regulation. When GLP-1 receptors are activated, it can lead to increased insulin secretion in a glucose-dependent manner, helping to lower blood sugar (PMID 42372276). It also slows gastric emptying, which can contribute to a feeling of fullness and reduced food intake (PMID 41956096). Furthermore, GLP-1 RAs are known to influence brain regions involved in appetite regulation, leading to reduced hunger and ultimately, weight loss (PMID 41760612, PMID 41956096). Its long-acting nature, supporting biweekly or once-weekly dosing, suggests a prolonged engagement with these receptors (PMID 41760612, PMID 42372276, PMID 41956096, PMID 42320483).

The catch: what we still don't know

While the findings for Bofanglutide are exciting, it's important to remember that this research is still in phase 2b clinical trials (PMID 41760612, PMID 42372276, PMID 41956096, PMID 42320483). This means larger, longer-term studies (Phase 3) will be crucial to confirm its efficacy and safety profile in a broader population before it can be considered for wider use (PMID 41956096, PMID 42320483).

The studies primarily involved Chinese participants (PMID 41760612, PMID 42442555, PMID 42372276, PMID 41956096, PMID 42320483), so further research is needed to understand how Bofanglutide might perform across different ethnic groups and demographics. The head-to-head comparison with semaglutide was open-label, which could introduce some bias, and the trial duration was relatively short at 24 weeks (PMID 42372276).

Moreover, while gastrointestinal side effects were generally mild to moderate, they were common. Understanding the long-term impact and management of these side effects will be key as research progresses (PMID 41760612, PMID 42372276).

Keep exploring

The journey of Bofanglutide from promising peptide to potential therapeutic is an exciting one to watch. As the science unfolds, we'll continue to keep you updated. In the meantime, dive deeper into the world of peptides by browsing our A–Z protocols, compare compounds, and share this article with fellow science enthusiasts! The future of metabolic health is constantly evolving, and peptides like Bofanglutide are at its forefront.

Sources

* Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial. Signal transduction and targeted therapy, 2026. https://pubmed.ncbi.nlm.nih.gov/41760612/ * Safety, tolerability, relative bioavailability, pharmacokinetics, and pharmacodynamics of single and multiple doses of the novel oral bofanglutide in healthy Chinese participants. Diabetes research and clinical practice, 2026. https://pubmed.ncbi.nlm.nih.gov/42442555/ * Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial. Annals of internal medicine, 2026. https://pubmed.ncbi.nlm.nih.gov/42372276/ * GZR18, a GLP-1 analog with once-weekly or bi-weekly dosing for body weight management: A randomized, placebo-controlled, phase 1b/2a trial. Cell reports. Medicine, 2026. https://pubmed.ncbi.nlm.nih.gov/41956096/ * Safety and efficacy of GZR18, a long-acting GLP-1 analog, in Chinese patients with type 2 diabetes: A randomized, double-blind, phase 1b/2a trial. Cell reports. Medicine, 2026. https://pubmed.ncbi.nlm.nih.gov/42320483/ * Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application. Journal of chromatography. A, 2026. https://pubmed.ncbi.nlm.nih.gov/42603384/